A phase I study of imexon plus gemcitabine as first-line therapy for advanced pancreatic cancer

被引：0
|
作者：
Steven J. Cohen
Mark M. Zalupski
Manuel R. Modiano
Paul Conkling
Yehuda Z. Patt
Peg Davis
Robert T. Dorr
Michelle L. Boytim
Evan M. Hersh
机构：
[1] Fox Chase Cancer Center,Department of Medical Oncology
[2] University of Michigan,undefined
[3] Arizona Clinical Research Center,undefined
[4] Virginia Oncology Associates,undefined
[5] US Oncology Phase I Group,undefined
[6] University of New Mexico,undefined
[7] University of Arizona,undefined
[8] AmpliMed Corporation,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2010年 / 66卷
关键词：
Gemcitabine; Imexon; Pancreatic cancer; Phase I clinical trial;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：287 / 294
页数：7
相关论文
共 50 条
  • [21] Gemcitabine plus paclitaxel as first-line chemotherapy for patients with advanced breast cancer
    Delfino, C
    Caccia, G
    Gonzáles, LR
    Mickiewicz, E
    Rodger, J
    Balbiani, L
    Morales, DF
    Comba, AZ
    Brosio, C
    ONCOLOGY, 2004, 66 (01) : 18 - 23
  • [22] A phase II study of cancer vaccination using three peptides combination with gemcitabine as a first-line therapy for advanced pancreatic cancer (VENUS-PC study)
    Iguchi, H.
    Suzuki, N.
    Uesugi, K.
    Tanaka, H.
    Hirakawa, K.
    Aruga, A.
    Hatori, T.
    Ishizaki, H.
    Umeda, Y.
    Fujiwara, T.
    Shimada, M.
    Ikemoto, T.
    Yoshimatsu, K.
    Shimizu, R.
    Hayashi, H.
    Sakata, K.
    Yoshino, S.
    Furukawa, H.
    Hazama, S.
    Oka, M.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S114 - S114
  • [23] Pancreatic Enzyme Replacement Therapy in Patients Undergoing First-Line Gemcitabine Plus nab-paclitaxel for Advanced Pancreatic Adenocarcinoma
    Trestini, Ilaria
    Carbognin, Luisa
    Peretti, Umberto
    Sperduti, Isabella
    Caldart, Alberto
    Tregnago, Daniela
    Avancini, Alice
    Auriemma, Alessandra
    Orsi, Giulia
    Pilotto, Sara
    Frulloni, Luca
    Capurso, Gabriele
    Bria, Emilio
    Reni, Michele
    Tortora, Giampaolo
    Milella, Michele
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [24] EFFICACY AND SAFETY OF GEMCITABINE AS FIRST-LINE THERAPY IN PATIENTS AGED 65 AND OLDER WITH ADVANCED PANCREATIC CANCER
    Kito, Yosuke
    Todaka, Akiko
    Fukutomi, Akira
    Kunieda, Kenji
    Tsushima, Takahiro
    Yokota, Tomoya
    Machida, Nozomu
    Yamazaki, Kentaro
    Onozawa, Yusuke
    Yasui, Hirofumi
    ANNALS OF ONCOLOGY, 2014, 25
  • [25] Details of response with first-line gemcitabine and nab-paclitaxel therapy in patients with advanced pancreatic cancer
    Nagata, Y.
    Kinoshita, C.
    Ishimoto, U.
    Kano, T.
    Ishikawa, M.
    Mikuni, H.
    Nakatsuka, K.
    Harada, K.
    Nishimura, T.
    Noguchi, M.
    Sawada, R.
    Amano, K.
    Saruta, M.
    ANNALS OF ONCOLOGY, 2019, 30
  • [26] Efficacy of Capecitabine Plus Oxaliplatin Combination Chemotherapy for Advanced Pancreatic Cancer after Failure of First-Line Gemcitabine-Based Therapy
    Chung, Kwang Hyun
    Ryu, Ji Kon
    Son, Jun Hyuk
    Lee, Jae Woo
    Jang, Dong Kee
    Lee, Sang Hyub
    Kim, Yong-Tae
    GUT AND LIVER, 2017, 11 (02) : 298 - 305
  • [27] Phase II randomized study of gemcitabine plus vinorelbine versus gemcitabine plus mitoxantrone in advanced metastatic breast cancer elderly women: A first-line chemotherapy
    Latorre, A.
    Monticelli, G.
    Giotta, F.
    Calabrese, R.
    Lorusso, V.
    Colucci, G.
    ANNALS OF ONCOLOGY, 2006, 17 : VII145 - VII146
  • [28] Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer
    Melisi, Davide
    Garcia-Carbonero, Rocio
    Macarulla, Teresa
    Pezet, Denis
    Deplanque, Gael
    Fuchs, Martin
    Trojan, Jorg
    Oettle, Helmut
    Kozloff, Mark
    Cleverly, Ann
    Smith, Claire
    Estrem, Shawn T.
    Gueorguieva, Ivelina
    Lahn, Michael M. F.
    Blunt, Al
    Benhadji, Karim A.
    Tabernero, Josep
    BRITISH JOURNAL OF CANCER, 2018, 119 (10) : 1208 - 1214
  • [29] Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer
    Davide Melisi
    Rocio Garcia-Carbonero
    Teresa Macarulla
    Denis Pezet
    Gael Deplanque
    Martin Fuchs
    Jorg Trojan
    Helmut Oettle
    Mark Kozloff
    Ann Cleverly
    Claire Smith
    Shawn T. Estrem
    Ivelina Gueorguieva
    Michael M. F. Lahn
    Al Blunt
    Karim A. Benhadji
    Josep Tabernero
    British Journal of Cancer, 2018, 119 : 1208 - 1214
  • [30] Sequential gemcitabine and platinum versus first-line combination of gemcitabine and platinum for advanced pancreatic cancer treatment: a retrospective study
    Guo, Jhe-Cyuan
    Yang, Shih-Hung
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2014, 19 (04) : 634 - 642
12345